Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy Tribal health issues
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
CENCORA, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Drug Shortages; supply chain resiliency; PAHPA Reauthorization; Drug Supply Chain Security Act (DSCSA) Implementation, SUPPORT Act Reauthorization, Appropriations bills (FDA, Labor, HHS). Issues related to vertical integration
Recognizing pharmacists as providers within Medicare; The Equitable Introduction of Community Access to Pharmacist Services Act Medicare reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
| CENTENE CORPORATION |
| 1 |
| 2026 |
| CHSPSC, LLC | 1 | 2026 |
| CONSENSUS CLOUD SOLUTIONS | 1 | 2026 |
| EMPOWER MENTAL HEALTH | 1 | 2026 |
| FERRING PHARMACEUTICALS, INC. | 1 | 2026 |
| GRINDR LLC | 1 | 2026 |
| HARMONY FOODS, LLC D/B/A SCN BESTCO, FORMALLY REPORTED AS, SANTA CRUZ HEALTHCARE | 1 | 2026 |
| KYVERNA THERAPEUTICS, INC. | 1 | 2026 |
| LIFEPOINT HEALTH | 1 | 2026 |
| LILLY USA, LLC | 1 | 2026 |
| NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS (N.A.C.H.)-CHA | 1 | 2026 |
| NOVARTIS | 1 | 2026 |
| Planet Fitness Holdings, LLC | 1 | 2026 |
| TAPESTRYHEALTH | 1 | 2026 |
| TENET BUSINESS SERVICES CORPORATION | 1 | 2026 |
| TEXAS CHILDREN'S HOSPITAL | 1 | 2026 |
| UNIVERSITY OF COLORADO HEALTH | 1 | 2026 |
Rural healthcare coverage and reimbursement Student loan repayment Competition issues Healthcare workforce and staffing issues Medicare and Medicaid reimbursement Medicaid provider tax State directed payments Rural Health Transformation Fund H.R.3108/ S.1535 RPM Access Act
Rural Patient Monitoring (RPM) Access Act
Client: LIFEPOINT HEALTH · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Rural healthcare coverage and reimbursement Student loan repayment Competition issues Healthcare workforce and staffing issues Medicare and Medicaid reimbursement Medicaid provider tax State directed payments Rural Health Transformation Fund H.R.3108/ S.1535 RPM Access Act
Patients Deserve Price Tags Act
Client: UNIVERSITY OF COLORADO HEALTH · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to Medicare coverage and reimbursement Issues related to hospital reforms and price transparency Medicaid provider tax issue State directed payments S.2355 - Patients Deserve Price Tags Act
Stroke Act
Client: ROMER INSTITUTE OF STROKE AND NEUROLOGY (RISN) · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Strategy to establish a CMMI pilot program related to stroke recovery and advocacy around the Stroke Act (S. 5260).
Stroke Act
Client: ROMER INSTITUTE OF STROKE AND NEUROLOGY (RISN) · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Strategy to establish a CMMI pilot program related to stroke recovery and advocacy around the Stroke Act (S. 5260).
BECTON, DICKINSON AND COMPANY via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Issues related to medical device reimbursement.
Issues related medical technology regulation.
Filing targets: State, Dept of (DOS)
TOLMAR, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Advocacy around issues affecting the pharmaceutical industry, such as the Medicare Drug Price Negotiation Program under the Inflation Reduction Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy Tribal health issues
Filing targets: Indian Health Service, SENATE
ABBVIE via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Issues related to patient access, pharmaceutical manufacturing, Patent reform, and drug pricing both domestic and international Issues realted to medicare drug pricing and reimbursement Direct to Consumer Advertising
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LIFEPOINT HEALTH via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Rural healthcare coverage and reimbursement Student loan repayment Competition issues Healthcare workforce and staffing issues Medicare and Medicaid reimbursement Medicaid provider tax State directed payments Rural Health Transformation Fund H.R.3108/ S.1535 RPM Access Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS (N.A.C.H.)-CHA via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
General issues of importance to children's hospitals Adovcacy for philanthropic opportunities for children's hospitals Children's healthcare coverage and reimbursement issues Issues related to CHGME Issues related to HHS Funding Medicaid provider tax State directed payments
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
KYVERNA THERAPEUTICS, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Outreach regarding cell therapies for autoimmune diseases.
Filing targets: Health & Human Services, Dept of (HHS)
CENTENE CORPORATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Issues related to ACA, Medicare Advantage, and Medicaid Issues related to Artificial Intelligence in healthcare issues related to healthcare affordability Regulatory policy related to LTC pharmaceutical services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY FOODS, LLC D/B/A SCN BESTCO, FORMALLY REPORTED AS, SANTA CRUZ HEALTHCARE via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Issues related to FDA, vitamins and dietary supplements, tariffs and supply chain
GRINDR LLC via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
HIV prevention, PEPFAR, family formation
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), Treasury, Dept of
FERRING PHARMACEUTICALS INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Issues related to microbiome, oncology, & fertility Issues related to formulary tier status Drug pricing policy Healthcare policy in the NDAA IVF Tax credit FDA Review programs
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Issues related to the pharmaceutical industry Treat and Reduce Obesity Act Pharmaceutical tariffs Safe Drugs Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PLANET FITNESS HOLDINGS, LLC via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Issues regarding health and wellness policies before Congress and the administration
Filing targets: Health & Human Services, Dept of (HHS), SENATE
CONSENSUS CLOUD SOLUTIONS via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Issues related to Healthcare, interoperability, digital cloud fax technology, and artificial intelligence
CHSPSC, LLC via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Issues related to healthcare policy Medicare area wage index Issues related to Medicare reimbursement Issues related to healthcare facility locations Medicaid provider tax State directed payments Rural healthcare workforce
Filing targets: SENATE, State, Dept of (DOS)
ROMER INSTITUTE OF STROKE AND NEUROLOGY (RISN) via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Strategy to establish a CMMI pilot program related to stroke recovery and advocacy around the Stroke Act (S. 5260).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TAPESTRYHEALTH via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Issues related to telehealth Telehealth Extension and Evaluation Act Physician coverage and reimbursement issues Remote monitoring Expanding Remote Monitoring Access Act RPM Cost Sharing Elimination Study Act Physician Fee Schedule Remote patient monitoring
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
TENET BUSINESS SERVICES CORPORATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Medicare coverage and reimbursement issues Medicaid coverage issues Medicaid provider tax issue State directed payments Issues related to ASC's Graduate medical education issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
TEXAS CHILDREN'S HOSPITAL via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Pediatric health care issues Medicaid coverage and reimbursement Maternal health Pediatric cancer research funding PACT ACT and CHGME Funding Global pediatric healthcare issues State directed payments
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ARDENT HEALTH SERVICES via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Medicare coverage and reimbursement issues Medicaid coverage issues Medicaid provider tax State directed payments Price transparency issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF COLORADO HEALTH via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Issues related to Medicare coverage and reimbursement Issues related to hospital reforms and price transparency Medicaid provider tax issue State directed payments S.2355 - Patients Deserve Price Tags Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROMER INSTITUTE OF STROKE AND NEUROLOGY (RISN) via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · RR
Strategy to establish a CMMI pilot program related to stroke recovery and advocacy around the Stroke Act (S. 5260).
BECTON, DICKINSON AND COMPANY via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · RR
Issues related to medical technology regulation. Issues related to medical device reimbursement. Medical device supply chain and international trade issues.
Issues related to medical technology regulation. Issues related to medical device reimbursement. Medical device supply chain and international trade issues.
Issues related to medical technology regulation. Issues related to medical device reimbursement. Medical device supply chain and international trade issues.
TOLMAR, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · RR
Advocacy around issues affecting the pharmaceutical industry, such as the Medicare Drug Price Negotiation Program under the Inflation Reduction Act.
EMPOWER MENTAL HEALTH via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · RR
Eligibility to deliver veteran healthcare services through the Community Care Network Next Generation (CCN Next Gen) program. Issues related to provider credentialing.